📌 Key Takeaways
- A peer-reviewed split-face RCT published on PubMed (July 8, 2026) compared Botox alone vs. Botox + Restylane Skinbooster Vital
in 24 Brazilian women with crow’s feet wrinkles. - The combination side showed superior canthal wrinkle severity scores and skin texture
at both 3 and 6 months post-treatment. - Patient satisfaction was significantly higher on the combination side at 3 months,
though the 24-subject sample limits generalizability. - The study signals a broader shift in aesthetic evaluation:
from “erasing wrinkles” to “improving overall skin quality.”
For decades, the answer to crow’s feet was straightforward:
inject botulinum toxin type A, suppress muscle movement, soften the lines.
It worked — and it still does.
But a randomized controlled trial published on PubMed on July 8, 2026
quietly complicates that picture.
A Brazilian research team designed a 24-subject, double-blind, split-face RCT
to ask a more nuanced question:
does adding a skin booster to Botox produce outcomes
that Botox alone cannot?
The answer, within the limits of this small trial,
is yes — and the difference lies not in wrinkle depth alone,
but in a dimension the field is increasingly calling “skin quality.”
INDEX
Why This Trial Design Matters: The Split-Face Method
A split-face trial treats the left and right sides of the same subject’s face under different conditions.
Because both sides belong to the same person, variables like age, skin type, lifestyle, and genetics are automatically controlled.
This makes it one of the most internally valid designs available in aesthetic medicine research.
Both sides received abobotulinumtoxinA injections.
One side additionally received Restylane Skinbooster Vital (hyaluronic acid skin booster).
The other side received a sham injection as placebo.
Evaluators and subjects were blinded to which side received which treatment.
Outcome measures included:
EMG activity (muscle activation), canthal wrinkle severity,
skin texture, and patient satisfaction scores.
What Is a Skin Booster — and How Is It Different from a Filler?
Restylane Skinbooster Vital is a hyaluronic acid (HA) preparation
injected in micro-doses into the superficial dermis.
Unlike volumizing fillers — which add structural projection —
skin boosters are designed to improve skin texture, smoothness, and quality from within.
They are available at select clinics globally, including in parts of Asia and Europe.
What the Trial Found: Beyond Wrinkle Reduction
Based on the published abstract and primary data review,
the trial’s key findings break down as follows:
Muscle suppression was achieved equally in both conditions —
confirming that the skin booster did not interfere with Botox’s primary mechanism.
favored the combination side at both 3-month and 6-month evaluations.
Note: hydration and elasticity metrics were not confirmed in the abstract
and are not reported here.
At 3 months, the combination side showed significantly higher satisfaction
than the Botox-only side.
This is a peer-reviewed, PubMed-indexed trial — but with 24 subjects, its statistical power is limited.
The direction of effect is meaningful.
The magnitude and optimal patient profile require larger replication studies.
NERO presents this as a directional signal, not a clinical mandate.
The Bigger Shift: From “Erasing Wrinkles” to “Improving Skin Quality”
The deeper implication of this trial is not simply “combine both treatments.”
It is a question about how we evaluate crow’s feet in the first place.
Evaluation axis: wrinkle depth and count.
Evaluation axis: wrinkle severity + skin texture + patient-reported satisfaction.
This is a small trial — 24 subjects — and its findings should be read accordingly.
But the conceptual reframe it represents is worth noting:
the shift from correcting a defect to elevating the baseline condition of the skin.
The gap between a clinic that answers “just get Botox” and one that says “let’s evaluate your skin quality together and design accordingly” — that gap is going to widen.
This trial is small, but it asks the right question: what are we actually measuring when we treat crow’s feet?
Before asking which treatments to combine,
patients benefit most from clarifying what they actually want to improve.
Is it the depth of the lines when smiling?
Or the overall impression of the eye area at rest?
The answer changes the optimal treatment design.
Summary
- A split-face RCT published July 8, 2026 (PubMed PMID 42420660) compared Botox alone
vs. Botox + Restylane Skinbooster Vital in 24 women with crow’s feet,
using the same subject’s left and right lateral canthus as the comparison unit. - The combination side showed better canthal wrinkle severity and skin texture scores
at 3 and 6 months, with significantly higher patient satisfaction at 3 months.
The 24-subject scale limits definitive conclusions. - The study’s most important contribution is conceptual:
it introduces skin texture as a co-equal outcome measure alongside wrinkle depth,
pointing toward a broader definition of treatment success. - Before consulting a provider, patients should clarify their own goals:
reducing visible lines, or improving the overall quality of the periorbital skin?
The answer shapes the optimal treatment plan.
Availability, regulatory approval status, and formulation details vary by country.
Patients should confirm the specific product and its approval status with their provider
before proceeding. The term “skin booster” is used broadly in aesthetic medicine
and covers products with significantly different compositions and concentrations.
Whether combination treatment is appropriate depends on individual anatomy,
skin condition, treatment goals, and clinical judgment.
The trial’s value is in expanding the evaluation framework — not in prescribing a universal protocol.
However, same-day administration in a controlled research setting
is distinct from same-day treatment in general clinical practice.
Timing, injection depth, product selection, and safety considerations
should be discussed individually with a qualified provider.
Source: PubMed PMID 42420660 — “AbobotulinumtoxinA combined with Restylane Skinbooster Vital for crow’s feet: A randomized, double-blind, split-face trial.” Published July 8, 2026. (Peer-reviewed; n=24; Brazil)
